Hutchison China Meditech Limited operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Hutchison China Meditech Limited with three other
miscellaneous service companies in Asia:
Takara Bio Inc
sales of 29.73 billion Japanese Yen [US$267.56 million]
of which 92%
was Bio support),
Syngene International Ltd
(11.07 billion Indian Rupees [US$171.92 million]
BGI Genomics Co Ltd
(1.71 billion Chinese Renmimbi [US$253.49 million]
of which 54%
was Reproductive Health Service).
Hutchison China Meditech Limited reported sales of 1.44 billion Chinese Renmimbi (US$212.96 million)
December of 2016.
increase of 28.3%
versus 2015, when the company's sales were 1.12 billion Chinese Renmimbi.
This was the third consecutive year of growth at Hutchison China Meditech Limited.
Sales of Consumer Products Prc saw an increase
that was more than double the company's growth rate: sales were up
144.0% in 2016, from
19.04 million Chinese Renmimbi to 46.47 million Chinese Renmimbi.
Hutchison China Meditech Limited also saw significant increases in sales in
Drugs Prc (up 50.3% to 997.08 million Chinese Renmimbi)
Consumer Products Hong Kong (up 43.7% to 159.73 million Chinese Renmimbi)
Not all segments of Hutchison China Meditech Limited experienced an increase in sales in 2016:
sales of Drug R and D fell 28.3% to 234.38 million Chinese Renmimbi.